Small Molecules

01 Apr 2017 Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkin’s Lymphoma
30 Mar 2017 Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
30 Mar 2017 Spero Therapeutics Receives $6.8 Million Award from CARB-X to Combat Antibiotic-Resistant Bacteria
30 Mar 2017 Forge Therapeutics Wins Powered by CARB-X Research Award of $8.8M to Accelerate Development of its LpxC Antibiotic to Kill the World's Deadliest 'Superbugs'
30 Mar 2017 Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma
30 Mar 2017 Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
30 Mar 2017 Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA(R)
29 Mar 2017 Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis
29 Mar 2017 Positive Results of Phase 2b Clinical Trial of Pharmalink's Nefecon in Primary IgA Nephropathy Published in The Lancet
29 Mar 2017 Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer
29 Mar 2017 Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
29 Mar 2017 Enrollment commences in phase III clinical study of Eisai’s BACE inhibitor elenbecestat in early Alzheimer’s disease in Japan
29 Mar 2017 Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis
28 Mar 2017 Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
28 Mar 2017 Cardax Astaxanthin Compound CDX-085 Stimulates Anti-Aging Gene in Mice
28 Mar 2017 Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome
28 Mar 2017 Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID as a Novel Target for Cancer Treatment at American Association of Cancer Research Annual Meeting
28 Mar 2017 Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
28 Mar 2017 Tesaro announces U.S. FDA approval of Zejula™ (niraparib) for women with recurrent ovarian cancer
27 Mar 2017 Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis
27 Mar 2017 Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501
27 Mar 2017 Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
27 Mar 2017 XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis (RA)
27 Mar 2017 Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia
27 Mar 2017 Kyowa Hakko Kirin Announces Top-Line Results of Japanese Phase 3 Clinical Study of ARQ197 (tivantinib) in Hepatocellular Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing